These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 15651132)

  • 1. Special report: genotyping for cytochrome P450 polymorphisms to determine drug-metabolizer status.
    Technol Eval Cent Assess Program Exec Summ; 2004 Dec; 19(9):1-2. PubMed ID: 15651132
    [No Abstract]   [Full Text] [Related]  

  • 2. Antipsychotic medications and ethnicity.
    Berg MJ
    J Gend Specif Med; 1998; 1(2):16-7. PubMed ID: 11281006
    [No Abstract]   [Full Text] [Related]  

  • 3. Radical differences in CYP1A1 genotype and function.
    Taioli E; Crofts F; Trachman J; Bayo S; Toniolo P; Garte SJ
    Toxicol Lett; 1995 May; 77(1-3):357-62. PubMed ID: 7618162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytochrome P450 pharmacogenetics in African populations: implications for public health.
    Dandara C; Swart M; Mpeta B; Wonkam A; Masimirembwa C
    Expert Opin Drug Metab Toxicol; 2014 Jun; 10(6):769-85. PubMed ID: 24588448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population distribution and effects on drug metabolism of a genetic variant in the 5' promoter region of CYP3A4.
    Ball SE; Scatina J; Kao J; Ferron GM; Fruncillo R; Mayer P; Weinryb I; Guida M; Hopkins PJ; Warner N; Hall J
    Clin Pharmacol Ther; 1999 Sep; 66(3):288-94. PubMed ID: 10511065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.
    Lee CR; Goldstein JA; Pieper JA
    Pharmacogenetics; 2002 Apr; 12(3):251-63. PubMed ID: 11927841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency of the frame-shifting CYP2D7 138delT polymorphism in a large, ethnically diverse sample population.
    Bhathena A; Mueller T; Grimm DR; Idler K; Tsurutani A; Spear BB; Katz DA
    Drug Metab Dispos; 2007 Aug; 35(8):1251-3. PubMed ID: 17494644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical practice, race, and drug use.
    Kalow W
    Clin Pharmacol Ther; 2003 Jan; 73(1):132-4. PubMed ID: 12545152
    [No Abstract]   [Full Text] [Related]  

  • 9. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations.
    Goldstein JA; Ishizaki T; Chiba K; de Morais SM; Bell D; Krahn PM; Evans DA
    Pharmacogenetics; 1997 Feb; 7(1):59-64. PubMed ID: 9110363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics of antimalarial drugs: effect on metabolism and transport.
    Kerb R; Fux R; Mörike K; Kremsner PG; Gil JP; Gleiter CH; Schwab M
    Lancet Infect Dis; 2009 Dec; 9(12):760-74. PubMed ID: 19926036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ethnic variation in the CYP2E1 gene: polymorphism analysis of 695 African-Americans, European-Americans and Taiwanese.
    Stephens EA; Taylor JA; Kaplan N; Yang CH; Hsieh LL; Lucier GW; Bell DA
    Pharmacogenetics; 1994 Aug; 4(4):185-92. PubMed ID: 7987402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement.
    Macphee IA; Fredericks S; Tai T; Syrris P; Carter ND; Johnston A; Goldberg L; Holt DW
    Transplantation; 2002 Dec; 74(11):1486-9. PubMed ID: 12490779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ethnic differences in the prevalence of the homozygous deleted genotype of glutathione S-transferase theta.
    Nelson HH; Wiencke JK; Christiani DC; Cheng TJ; Zuo ZF; Schwartz BS; Lee BK; Spitz MR; Wang M; Xu X
    Carcinogenesis; 1995 May; 16(5):1243-5. PubMed ID: 7767992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of cytochrome P450 2E1 genetic polymorphisms in relation to human lung cancer.
    Kato S; Shields PG; Caporaso NE; Sugimura H; Trivers GE; Tucker MA; Trump BF; Weston A; Harris CC
    Cancer Epidemiol Biomarkers Prev; 1994 Sep; 3(6):515-8. PubMed ID: 8000304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype.
    MacPhee IA; Holt DW
    Transplantation; 2008 Jan; 85(2):163-5. PubMed ID: 18212618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Ethnicity in pharmacogenetics].
    Sontoredjo TA; de Boer A; Maitland-van der Zee AH
    Ned Tijdschr Geneeskd; 2013; 157(17):A6118. PubMed ID: 23614867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of sex, ethnicity, and CYP2B6 genotype on bupropion metabolism as an index of hepatic CYP2B6 activity in humans.
    Ilic K; Hawke RL; Thirumaran RK; Schuetz EG; Hull JH; Kashuba AD; Stewart PW; Lindley CM; Chen ML
    Drug Metab Dispos; 2013 Mar; 41(3):575-81. PubMed ID: 23238783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The future of warfarin pharmacogenetics in under-represented minority groups.
    Cavallari LH; Perera MA
    Future Cardiol; 2012 Jul; 8(4):563-76. PubMed ID: 22871196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cytochrome P450 2C19 gene polymorphism in four Chinese nationality populations].
    Zhang S; Dong Z; Tang L; Zhou Q; Wu Z
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2002 Feb; 19(1):52-4. PubMed ID: 11836688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population.
    Solus JF; Arietta BJ; Harris JR; Sexton DP; Steward JQ; McMunn C; Ihrie P; Mehall JM; Edwards TL; Dawson EP
    Pharmacogenomics; 2004 Oct; 5(7):895-931. PubMed ID: 15469410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.